Anticoagulation in Intracerebral Hemorrhage (ICH) Survivors for Stroke Prevention and Recovery (ASPIRE)

Date Added
October 7th, 2019
PRO Number
Pro00092649
Researcher
Christine Holmstedt

List of Studies

Keywords
Stroke
Summary

The purpose of the study is to compare the effects of apixaban (also known as Eliquis®) with aspirin in patients with atrial fibrillation and a recent brain hemorrhage to see which is better in preventing strokes and death.

Subjects will be in the research study for up to 3 years (minimum of 1 year). About 700 people will take part in this study at approximately 125 sites throughout the United States.

Institution
MUSC
Recruitment Contact
Vicki Streets
843-792-7118
streetsv@musc.edu

Coordinated, Collaborative, Comprehensive, Family-Based, Integrated, and Technology-Enabled Care: A Comparative Effectiveness Randomized Trial To Improve Stroke Care Delivery

Date Added
September 24th, 2019
PRO Number
Pro00090574
Researcher
Christine Holmstedt

List of Studies

Keywords
Stroke
Summary

C3FIT is a randomized trial to determine the most effective way for hospitals to take care of stroke patients after they are discharged by comparing two plans. Plan 1 is the usual standard of care way performed at Comprehensive/Primary Stroke Centers and developed by the Amercian Heart Association and the Joint Comissiona. Plan 2 is the same as Plan 1 PLUS in-home rehabilitation. MUSC has been selected as a study site for Plan 1 only.

Patients over the age of 18 with a clinical diagnosis of acute stroke with brain imaging with intracerebral hemorrhage or ischemic stroke are eligible who meet addtional study qualification requirements. Total duration of participation is 2 years. Study enrollment will be performed at approximately 18 sites for a total enrollment goal of 1800 patients, 100 per site.

Data from C3FIT may be used to help identify the best methods for health systems to use in managing stroke patients.

Institution
MUSC
Recruitment Contact
Ariana Tinker
843-792-6881
tinkera@musc.edu

ARCADIA-CSI (Cognition and Silent Infarcts)

Date Added
July 31st, 2019
PRO Number
Pro00091520
Researcher
Christine Holmstedt

List of Studies

Keywords
Stroke
Summary

This is a research study looking to compare the effects (good and bad) of the ARCADIA study drugs (apixaban and aspirin) on the occurrence of silent strokes and memory loss after stroke.

This add-on study to the ARCADIA trial involves cognitive testing (tests designed to measure subjects memory, thinking, reasoning and understanding) and an MRI scan of their brain.

There will be about 5 study visits over the length of the study (approximately 3 years), or for a long as subjects are in the parent ARCADIA study.

Institution
MUSC
Recruitment Contact
Vicki Streets
843-792-8606
streetsv@musc.edu

A Phase III, Prospective, Double-Blind, Randomized, Placebo-Controlled Trial of Thrombolysis in Imaging-Eligible, Late-Window Patients To Assess the Efficacy and Safety of Tenecteplase

Date Added
March 26th, 2019
PRO Number
Pro00086659
Researcher
Christine Holmstedt

List of Studies

Keywords
Stroke
Summary

The purpose of this research study is to evaluate the desired outcome and safety of the study drug, tenecteplase, compared to a placebo in patients with an acute ischemic stroke. Tenecteplase is approved by the health authorities for the treatment of heart attack, but it is not approved for stroke.

Participants will be screened within 4.5 to 24 hours after the onset of the stroke and will undergo 2 followup MRIs within 96 hours.

Follow-up clinic visits will occur at 30 and 90 days after study treatment. Total study duration is about 3 months.

Institution
MUSC
Recruitment Contact
Vicki Streets
(843)-792-8606
streetsv@musc.edu

AtRial Cardiopathy and Antithrombotic Drugs in prevention After cryptogenic stroke

Date Added
January 10th, 2018
PRO Number
Pro00072371
Researcher
Christine Holmstedt

List of Studies

Keywords
Cardiovascular, Heart, Hypertension/ High Blood Pressure, Stroke, Stroke Recovery
Summary

ARCADIA is a multicenter, biomarker-driven, randomized, double-blind, active-control, phase 3 clinical trial of apixaban (Eliquis) versus aspirin in patients who have evidence of atrial cardiopathy and a recent stroke of unknown cause. 1100 subjects will be recruited over 6 years at 120 sites in the NINDS StrokeNet consortium. Subjects will be followed for a minimum of 1.5 years and a maximum of 7 years for the primary efficacy outcome of recurrent stroke and the primary safety outcomes of symptomatic intracranial hemorrhage and major hemorrhage other than intracranial hemorrhage.

Institution
MUSC
Recruitment Contact
Cheryl Grant
843-792-8606
streetsv@musc.edu



-- OR --